Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | USP14 | P54578 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11063847 | 0.82 | HTR2A (0.49) | PTGS1PTGS2HTR6MCHR1KDM4E | |
| Hydrochloric Acid SCHEMBL31078325 | 0.82 | MAPT (0.49) | PTGS1PTGS2CYP3A4HTR6MCHR1 | |
| SCHEMBL4892347 | 0.81 | PTGS1 (0.46) | PTGS1PTGS2CYP3A4HTR6MCHR1 | |
| Hydrochloric Acid SCHEMBL31078525 | 0.81 | KDM4E (0.50) | PTGS1PTGS2HTR6MCHR1KDM4E | |
| SCHEMBL4892790 | 0.77 | HDAC1 (0.50) | PTGS1PTGS2CYP3A4HTR6SIRT2 | |
| SCHEMBL10378638 | 0.75 | CYP3A4 (0.49) | CYP3A4 | |
| Hydrochloric Acid SCHEMBL11199199 | 0.74 | CYP3A4 (0.48) | CYP3A4 | |
| SCHEMBL10957585 | 0.72 | HTR2C (0.62) | HTR6KDM4E | |
| Hydrochloric Acid SCHEMBL31078540 | 0.71 | HTR6 (0.48) | HTR6MCHR1KDM4E | |
| SCHEMBL21121272 | 0.71 | CYP3A4 (0.46) | CYP3A4HTR6SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280941-A1 | 8-Phenoxy-Gamma Carboline Derivatives | PHARMA C S.A. (FR) | 2008-11-13 | — | — | US | claimed |
| EP-1756102-A1 | 8-PHENOXY-GammaCARBOLINE DERIVATIVES | Pharma C S.A. (FR) | 2007-02-28 | — | — | EP | claimed |
| WO-2005095396-A1 | 8-PHENOXY-Ϝ CARBOLINE DERIVATIVES | PHARMA C S.A. (FR) | 2005-10-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280941-A1 | 8-Phenoxy-Gamma Carboline Derivatives | CHRNA7, ADRA2C, CHRNE | PTGS1 249/4885PTGS2 268/4885CYP3A4 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.